title: Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy.
abstract: BACKGROUND
  The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.
  
  
  METHODS
  We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni- and multivariable cox regression models addressed the association of statin use with BCR.
  
  
  RESULTS
  Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values 0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.
  
  
  CONCLUSIONS
  In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.
authors.affiliation: 1] Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA [2] Department of Urology, University Hospital Basel, Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Rieken
authors.forename: L A
authors.initials: LA
authors.lastname: Kluth
authors.forename: E
authors.initials: E
authors.lastname: Xylinas
authors.forename: C
authors.initials: C
authors.lastname: Seitz
authors.forename: H
authors.initials: H
authors.lastname: Fajkovic
authors.forename: P I
authors.initials: PI
authors.lastname: Karakiewicz
authors.forename: Y
authors.initials: Y
authors.lastname: Lotan
authors.forename: A
authors.initials: A
authors.lastname: Briganti
authors.forename: W
authors.initials: W
authors.lastname: Loidl
authors.forename: T
authors.initials: T
authors.lastname: Faison
authors.forename: J J
authors.initials: JJ
authors.lastname: Crivelli
authors.forename: D S
authors.initials: DS
authors.lastname: Scherr
authors.forename: A
authors.initials: A
authors.lastname: Bachmann
authors.forename: A K
authors.initials: AK
authors.lastname: Tewari
authors.forename: A
authors.initials: A
authors.lastname: Kautzky-Willer
authors.forename: K
authors.initials: K
authors.lastname: Pummer
authors.forename: S F
authors.initials: SF
authors.lastname: Shariat
mesh_terms: D000368:Aged; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017430:Prostate-Specific Antigen